The University of Wisconsin Research Foundation’s Bridge Grant Program bolsters efforts to commercialize innovations developed at the UWM and foster development of startup companies that improve the Wisconsin economy. The program leverages a grant from the Wisconsin Economic Development Corporation (WEDC) Capital Catalyst Program to invest in early-stage enterprises based on UWM technologies. Pantherics received $38,000 to further develop PI301 as first-in-class oral asthma drug. Estrigenix received $25,000 to perform preclinical evaluations of their estrogen receptor agonist for the treatment of hot flashes. The MIDD supports both companies by providing a modern drug development infrastructure and will complete specific non-GLP preclinical studies.